AN2 Historical Balance Sheet

ANTX Stock

USD 1.37 0.02 1.44%

Trend analysis of AN2 Therapeutics balance sheet accounts such as Short Long Term Debt Total of 45.3 K, Other Current Liabilities of 11.9 M or Total Current Liabilities of 14.7 M provides information on AN2 Therapeutics' total assets, liabilities, and equity, which is the actual value of AN2 Therapeutics to its prevalent stockholders. By breaking down trends over time using AN2 Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining AN2 Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AN2 Therapeutics is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AN2 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.

About AN2 Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of AN2 Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. AN2 Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of AN2 Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which AN2 currently owns. An asset can also be divided into two categories, current and non-current.

AN2 Therapeutics Balance Sheet Chart

At this time, AN2 Therapeutics' Other Current Liabilities is fairly stable compared to the past year. Total Current Liabilities is likely to rise to about 14.7 M in 2024, whereas Total Assets are likely to drop slightly above 69.6 M in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Total Assets

Total assets refers to the total amount of AN2 Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in AN2 Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on AN2 Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of AN2 Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from AN2 Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into AN2 Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AN2 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.At this time, AN2 Therapeutics' Other Current Liabilities is fairly stable compared to the past year. Total Current Liabilities is likely to rise to about 14.7 M in 2024, whereas Total Assets are likely to drop slightly above 69.6 M in 2024.

	2023	2024 (projected)
Short and Long Term Debt Total	47.7K	45.3K
Total Assets	138.7M	69.6M

Short Long Term Debt Total Total Assets

AN2 Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Other Liab	Other Stockholder Equity	Net Invested Capital	Net Working Capital	Non Currrent Assets Other	Other Assets	Deferred Long Term Liab	Property Plant And Equipment Net	Non Current Liabilities Other	Short Term Debt
Total Assets		-0.79	0.86	0.88	0.75	0.78	-0.88	-0.92	0.93	0.87	0.99	0.81	0.19	1.0	0.33	1.0	-0.96	0.79	0.83	0.99	-0.85	-0.86	-0.56	-0.56	-0.56	-0.56
Short Long Term Debt Total	-0.79		-0.76	-0.77	-0.49	-0.55	0.75	0.8	-0.81	-0.7	-0.8	-0.59	-0.44	-0.81	-0.57	-0.8	0.85	-0.6	-0.64	-0.83	0.69	0.69	0.53	0.53	0.53	0.53
Other Current Liab	0.86	-0.76		1.0	0.88	0.89	-0.72	-0.99	0.96	0.67	0.83	0.94	-0.01	0.85	0.15	0.83	-0.82	0.93	0.93	0.86	-0.83	-0.98	-0.9	-0.9	-0.9	-0.9
Total Current Liabilities	0.88	-0.77	1.0		0.89	0.9	-0.76	-1.0	0.98	0.71	0.86	0.93	0.01	0.88	0.17	0.86	-0.85	0.93	0.94	0.89	-0.86	-0.98	-0.88	-0.88	-0.88	-0.88
Total Stockholder Equity	0.75	-0.49	0.88	0.89		1.0	-0.73	-0.87	0.87	0.7	0.74	0.85	-0.43	0.75	-0.27	0.74	-0.64	0.99	0.98	0.76	-0.91	-0.96	-0.79	-0.79	-0.79	-0.79
Net Tangible Assets	0.78	-0.55	0.89	0.9	1.0		-0.78	-0.89	0.89	0.75	0.78	0.84	-0.38	0.79	-0.22	0.78	-0.68	0.99	0.99	0.8	-0.94	-0.96	-0.77	-0.77	-0.77	-0.77
Net Debt	-0.88	0.75	-0.72	-0.76	-0.73	-0.78		0.8	-0.87	-0.99	-0.92	-0.55	-0.11	-0.89	-0.24	-0.92	0.89	-0.74	-0.8	-0.93	0.94	0.77	0.45	0.45	0.45	0.45
Retained Earnings	-0.92	0.8	-0.99	-1.0	-0.87	-0.89	0.8		-0.99	-0.75	-0.9	-0.92	-0.04	-0.91	-0.21	-0.9	0.88	-0.92	-0.94	-0.92	0.88	0.98	0.84	0.84	0.84	0.84
Accounts Payable	0.93	-0.81	0.96	0.98	0.87	0.89	-0.87	-0.99		0.83	0.93	0.86	0.08	0.93	0.24	0.93	-0.92	0.91	0.93	0.96	-0.92	-0.96	-0.79	-0.79	-0.79	-0.79
Cash	0.87	-0.7	0.67	0.71	0.7	0.75	-0.99	-0.75	0.83		0.91	0.51	0.1	0.88	0.22	0.91	-0.87	0.7	0.76	0.92	-0.92	-0.73	-0.37	-0.37	-0.37	-0.37
Cash And Short Term Investments	0.99	-0.8	0.83	0.86	0.74	0.78	-0.92	-0.9	0.93	0.91		0.76	0.21	1.0	0.35	1.0	-0.97	0.77	0.82	0.99	-0.87	-0.84	-0.53	-0.53	-0.53	-0.53
Common Stock Shares Outstanding	0.81	-0.59	0.94	0.93	0.85	0.84	-0.55	-0.92	0.86	0.51	0.76		-0.14	0.79	0.02	0.76	-0.7	0.89	0.87	0.76	-0.7	-0.93	-0.83	-0.83	-0.83	-0.83
Non Current Liabilities Total	0.19	-0.44	-0.01	0.01	-0.43	-0.38	-0.11	-0.04	0.08	0.1	0.21	-0.14		0.19	0.99	0.21	-0.4	-0.34	-0.28	0.22	0.17	0.17	0.13	0.13	0.13	0.13
Other Current Assets	1.0	-0.81	0.85	0.88	0.75	0.79	-0.89	-0.91	0.93	0.88	1.0	0.79	0.19		0.34	1.0	-0.96	0.79	0.83	0.99	-0.86	-0.86	-0.55	-0.55	-0.55	-0.55
Total Liab	0.33	-0.57	0.15	0.17	-0.27	-0.22	-0.24	-0.21	0.24	0.22	0.35	0.02	0.99	0.34		0.35	-0.54	-0.18	-0.12	0.37	0.02	0.0	-0.02	-0.02	-0.02	-0.02
Total Current Assets	1.0	-0.8	0.83	0.86	0.74	0.78	-0.92	-0.9	0.93	0.91	1.0	0.76	0.21	1.0	0.35		-0.97	0.77	0.82	0.99	-0.87	-0.84	-0.53	-0.53	-0.53	-0.53
Other Liab	-0.96	0.85	-0.82	-0.85	-0.64	-0.68	0.89	0.88	-0.92	-0.87	-0.97	-0.7	-0.4	-0.96	-0.54	-0.97		-0.68	-0.74	-0.98	0.8	0.79	0.56	0.56	0.56	0.56
Other Stockholder Equity	0.79	-0.6	0.93	0.93	0.99	0.99	-0.74	-0.92	0.91	0.7	0.77	0.89	-0.34	0.79	-0.18	0.77	-0.68		1.0	0.79	-0.91	-0.98	-0.83	-0.83	-0.83	-0.83
Net Invested Capital	0.83	-0.64	0.93	0.94	0.98	0.99	-0.8	-0.94	0.93	0.76	0.82	0.87	-0.28	0.83	-0.12	0.82	-0.74	1.0		0.84	-0.94	-0.98	-0.81	-0.81	-0.81	-0.81
Net Working Capital	0.99	-0.83	0.86	0.89	0.76	0.8	-0.93	-0.92	0.96	0.92	0.99	0.76	0.22	0.99	0.37	0.99	-0.98	0.79	0.84		-0.89	-0.87	-0.59	-0.59	-0.59	-0.59
Non Currrent Assets Other	-0.85	0.69	-0.83	-0.86	-0.91	-0.94	0.94	0.88	-0.92	-0.92	-0.87	-0.7	0.17	-0.86	0.02	-0.87	0.8	-0.91	-0.94	-0.89		0.9	0.64	0.64	0.64	0.64
Other Assets	-0.86	0.69	-0.98	-0.98	-0.96	-0.96	0.77	0.98	-0.96	-0.73	-0.84	-0.93	0.17	-0.86	0.0	-0.84	0.79	-0.98	-0.98	-0.87	0.9		0.86	0.86	0.86	0.86
Deferred Long Term Liab	-0.56	0.53	-0.9	-0.88	-0.79	-0.77	0.45	0.84	-0.79	-0.37	-0.53	-0.83	0.13	-0.55	-0.02	-0.53	0.56	-0.83	-0.81	-0.59	0.64	0.86		1.0	1.0	1.0
Property Plant And Equipment Net	-0.56	0.53	-0.9	-0.88	-0.79	-0.77	0.45	0.84	-0.79	-0.37	-0.53	-0.83	0.13	-0.55	-0.02	-0.53	0.56	-0.83	-0.81	-0.59	0.64	0.86	1.0		1.0	1.0
Non Current Liabilities Other	-0.56	0.53	-0.9	-0.88	-0.79	-0.77	0.45	0.84	-0.79	-0.37	-0.53	-0.83	0.13	-0.55	-0.02	-0.53	0.56	-0.83	-0.81	-0.59	0.64	0.86	1.0	1.0		1.0
Short Term Debt	-0.56	0.53	-0.9	-0.88	-0.79	-0.77	0.45	0.84	-0.79	-0.37	-0.53	-0.83	0.13	-0.55	-0.02	-0.53	0.56	-0.83	-0.81	-0.59	0.64	0.86	1.0	1.0	1.0

Click cells to compare fundamentals

AN2 Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for AN2 Stock Analysis

When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AN2 Historical Balance Sheet

About AN2 Balance Sheet Analysis

AN2 Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

AN2 Therapeutics balance sheet Correlations

AN2 Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for AN2 Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Other Current Assets	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 1.0	Cash And Short Term Investments

Retained Earnings	- 1.0	Total Current Liabilities
Accounts Payable	- 0.99	Retained Earnings
Cash	- 0.99	Net Debt
Retained Earnings	- 0.99	Other Current Liab
Other Assets	- 0.98	Net Invested Capital
Other Assets	- 0.98	Other Stockholder Equity